Delirium in the Course of Cancer Treatment

Seminars in Clinical Neuropsychiatry

Volumn 8, Issue 4, 2003, Pages 217-228

  Fann, Jesse R ^a   Sullivan, Arthur K ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMPICILLIN; ANTIBIOTIC AGENT; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; ASPARAGINASE; CEPHALOSPORIN DERIVATIVE; CHLORAMBUCIL; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; CYTARABINE; DIPHENHYDRAMINE; ERYTHROPOIETIN; GANCICLOVIR; GENTAMICIN; IFOSFAMIDE; LORAZEPAM; METOCLOPRAMIDE; ONDANSETRON; OPIATE; PIPERACILLIN; QUINOLONE DERIVATIVE; TICARCILLIN; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN; VINBLASTINE; VINCRISTINE;

ANXIETY DISORDER; CANCER CHEMOTHERAPY; CANCER PAIN; CANCER PATIENT; CARCINOMA; COGNITIVE DEFECT; CONFUSION; DELIRIUM; DEPRESSION; DIAGNOSTIC PROCEDURE; DISEASE ACTIVITY; ELDERLY CARE; EPIDEMIOLOGICAL DATA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPONATREMIA; IMMUNOTHERAPY; INCIDENCE; MANIA; METABOLIC DISORDER; PATHOPHYSIOLOGY; PERCEPTION DISORDER; PREVALENCE; REVIEW; RISK FACTOR; SIDE EFFECT;

EID: 0345107252     PISSN: 10843612     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (116)

1. Diagnostic and Statistical Manual of Mental Disorders: Text Revision, 4th ed. Washington, DC: American Psychiatric Association, 2000
2. Cole MG, Primeau FJ: Prognosis of delirium in elderly hospital patients. Can Med Assoc J 149:49-46, 1993
3. Bruera E, Spachynsky K, MacEachern T, et al: Cognitive failure in cancer patients in clinical trials. Lancet 341:247-248, 1993
4. Coyle N, Breitbart W, Weaver S, et al: Delirium as a contributing factor to crescendo pain: three case reports. J Pain Symptom Manage 9:44-47, 1994
5. Gagnon B, Lawlor PG, Mancini IL, et al: The impact of delirium on the circadian distribution of breakthrough analgesia in advanced cancer patients. J Pain Symptom Manage 22:826-833, 2001
6. Fann JR, Burington B, Roth-Roemer S, et al: Delirium and affective and cognitive outcomes in patients undergoing stem cell transplantation. Ann Behav Med 23(suppl):64, 2001
7. Breitbart W, Gibson C, Tremblay A: The delirium experience: delirium recall and delirium-related distress in hospitalized patients with cancer, their spouses/caregivers, and their nurses. Psychosomatics 43:183-194, 2002
8. Hallberg IR: Impact of delirium on professionals. Dement Geriatr Cogn Disord 10:420-425, 1999
9. Caraceni A, Nanni O, Maltoni M, et al: Impact of delirium on the short term prognosis of advanced cancer patients. Cancer 89:1145-1149, 2000
10. Tuma R, DeAngelis LM: Altered mental status in patients with cancer. Arch Neurol 57:1727-1731, 2000
11. McCusker J, Cole M, Abrahamowicz M, et al: Delirium predicts 12-month mortality. Arch Intern Med 162:457-463, 2000
12. van Hemert AM, van der Mast RC, Hengeveld MW, et al: Excess mortality in general hospital patients with delirium: a 5-year follow-up of 519 patients seen in psychiatric consultation. J Psychosom Res 38:339-346, 1994
13. Inouye SK: The dilemma of delirium. Am J Med 97:278-288, 1994
14. Breitbart W, Rosenfeld B, Roth A, et al: The Memorial Delirium Assessment Scale. J Pain Symptom Manage 13:128-137, 1997
15. Armstrong SC, Cozza KL, Watanabe KS: The misdiagnosis of delirium. Psychosomatics 38:433-439, 1997
16. O'Keeffe S, Lavan J: The prognostic significance of delirium in older hospital patients. J Am Geriatr Soc 45:174-178, 1997
17. Inouye SK, Rushing JT, Foreman MD, et al: Does delirium contribute to poor hospital outcomes? A three-site epidemiologic study. J Gen Intern Med 13:234-242, 1998
18. Rogers M, Liang M, Daltroy L: Delirium after elective orthopedic surgery: risk factors and natural history. Int J Psychiatry Med 19:109-121, 1989
19. Olofsson SM, Weitzner MA, Valentine AD, et al: A retrospective study of the psychiatric management and outcome of delirium in the cancer patient. Support Care Cancer 4:351-357, 1996
20. Tombaugh TN, McIntyre NJ: The Mini-Mental State Examination: a comprehensive review. J Am Geriatr Soc 40:922-935, 1992
21. Smith MJ, Breitbart WS, Platt MM: A critique of instruments and methods to detect, diagnose, and rate delirium. J Pain Symptom Manage 10:35-77, 1995
22. Trzepacz P, Baker R, Greenhouse J: A symptom rating scale for delirium. Psychiatric Research 23:89-97, 1988
23. Lawlor PG, Nekolaichuk C, Gagnon B, et al: Clinical utility, factor analysis, and further validation of the Memorial Delirium Assessment Scale in patients with cancer. Cancer 88:2859-2867, 2000
24. Inouye SK, van Dyck CH, Alessie CA, et al: Clarifying confusion: the confusion assessment method, a new method for the detection of delirium. Ann Intern Med 113:941-948, 1990
25. Macleod AD, Whitehead LE: Dysgraphia and terminal delirium. Palliat Med 11:127-132, 1997
26. Morita T, Tsunoda J, Inoue S, et al: Communication capacity scale and agitation distress scale to measure the severity of delirium in terminally ill cancer patients: a validation study. Palliat Med 15:197-206, 2001
27. Sarhill N, Walsh D, Nelson K, et al: Assessment of delirium in advanced cancer: the use of the bedside confusion scale. Am J Hosp Pal Care 18:335-341, 2001
28. Jacobson S, Jerrier H: EEG in delirium. Semin Clin Neuropsychiatry 5:86-92, 2000
29. Fann JR: The epidemiology of delirium. Semin Clin Neuropsychiatry 5:64-74, 2000
30. Weinrich S, Sarna L: Delirium in the older person with cancer. Cancer 74:2079-2091, 1994
31. Stiefel F, Holland J: Delirium in cancer patients. Int Psychogeriatr 3:333-336, 1991
32. Stiefel F, Fainsinger R, Bruera E: Acute confusional states in patients with advanced cancer. J Pain Symptom Manage 7:94-98, 1992
33. Fann JR, Roth-Roemer S, Burington B, et al: Delirium in patients undergoing hematopoietic stem cell transplantation: incidence and pretransplantation risk factors. Cancer 95:1971-1981, 2002
34. Massie MJ, Holland J, Glass E: Delirium in terminally ill cancer patients. Am J Psychiatry 140:1048-1050, 1983
35. Gagnon P, Allard P, Masse B, et al: Delirium in terminal cancer: A prospective study using daily screening, early diagnosis and continuous monitoring. J Pain Symptom Manage 19:412-426, 2000
36. Lawlor PG, Gagnon B, Mancini IL, et al: Occurrence, causes, and outcome of delirium in patients with advanced cancer. Arch Intern Med 160:786-794, 2000
37. Casarett D, Inouye S: Diagnosis and management of delirium near the end of life. Ann Intern Med 135:32-40, 2001
38. Minagawa H, Uchitomi Y, Yamawaki S, et al: Psychiatric morbidity in terminally ill cancer patients. Cancer 78:1131-1137, 1996
39. Luck SJ, Hillyard SA: The operation of selective attention at multiple stages of processing evidence from human and monkey electrophysiology. In: Gazzaniga MS, ed. The New Cognitive Neurosciences, ed 2. Cambridge, MA: MIT Press, 2000, 687-700
40. Mangun GR, Jha AP, Hopfinger JP, et al: The temporal dynamics and functional architecture of attentional processes in human extrastriate cortex: In: Gazzaniga MS, ed. The New Cognitive Neurosciences ed 2. Cambridge, MA: MIT Press, 2000, 701-710
41. LaBerge D: Networks of attention. In: Gazzaniga MS, ed. The New Cognitive Neurosciences, ed 2. Cambridge, MA: MIT Press, 2000, 711-724
42. Landis DMD: Brain as tissue: the interacting cell populations of the nervous system. In: Rabsohoff RM, Benveniste EN, eds. Cytokines and the CNS. Boca Raton, FL: CRC Press, Inc, 1996, 63-83
43. Blass JP, Gibson GE: Cerebrometabolic aspects of delirium in relationship to dementia. Dement Geriatr Cogn Disord 10:335-338, 1999
44. Tune LE: Serum anticholinergic activity levels and delirium in the elderly. Semin Clin Neuropsychiatry 5:149-153, 2000
45. Flacker JM, Wei JY: Endogenous anticholinergic substances may exist during acute illness in elderly medical patients. J Gerontol 56A:M353-M355, 2001
46. van der Mast RC: Pathophysiology of delirium. J Geriatr Psychiatry Neurol 11:138-145, 1998
47. Trzepacz P: Update on the neuropathogenesis of delirium. Dement Geriatr Cogn Disord 10:330-334, 1999
48. Trzepacz P: Is there a final common neural pathway in delirium? Focus on acetylcholine and dopamine. Semin Clin Neuropsychiatry 5:132-148, 2000
49. Van der Mast RC, Fekkes D: Serotonin and amino acids: partners in delirium pathophysiology? Semin Clin Neuropsychiatry 5:125-131, 2000
50. Olsson T: Activity of the hypothalamic-pituitary-adrenal axis and delirium. Dement Geriatr Cogn Disord 10:345-349, 1999
51. Clouston PD, DeAngelis LM, Posner JB: The spectrum of neurological disease in patients with systemic cancer. Ann Neurol 31:268-273, 1992
52. Bruera E, Neumann CM: The uses of psychotropics in symptom management in advanced cancer. Psychooncology 7:346-358, 1998
53. Morita T, Tei Y, Tsunoda J, et al: Underlying pathologies and their associations with clinical features in terminal delirium of cancer patients. J Pain Symptom Manage 22:997-1006, 2001
54. Cocito L, Audenino D, Primavera A: Altered mental state and nonconvulsive status epilepticus in patients with cancer. Arch Neurol 58:1310, 2001
55. Devlin T, Moll S, Hulette C, et al: Intravascular malignant lymphomatosis with neurologic presentation: factors facilitating antemortem diagnosis. South Med J 91:672-676, 1998
56. Baile WF: Neuropsychiatric disorders in cancer patients. Curr Opin Oncol 8:182-187, 1996
57. Musha M, Tanaka F, Ohuti M: Psychoses in three cases with myasthenia gravis and thymoma-proposal of a paraneoplastic autoimmune neuropsychiatric syndrome. Tohoku J Exp Med 169:335-344, 1993
58. Taanaka F, Imanaka F, Hayashi Y, et al: A patient with ammonia-producing multiple myeloma showing hyperammonemic encephalopathy. Leukemia 10:918-919, 1996
59. Siddiqui T, Deshmukh VD, Karimjee N: Subclinical cognitive deficits in cancer patients: a preliminary study. Clin Electroencephalogr 23:132-136, 1992
60. Meyers CA, Byrne CA, Komaki R: Cognitive defects in patients with small cell lung cancer before and after chemotherapy. Lung Cancer 12:231-235, 1995
61. Zeimer H: Paraneoplastic limbic encephalitis should not be overlooked as a possible cause of delirium in cancer patients. Arch Intern Med 160:2866, 2000
62. Carter GL, Dawson AH, Lopert R: Drug-induced delirium. Drug Safety 15:291-301, 1996
63. Brown TM: Drug-induced delirium. Semin Clin Neuropsychiatry 5:113-124, 2000
64. Drugs that may cause psychiatric symptoms. Med Lett Drugs Ther 44:59-62, 2002
65. Han L, McCusker J, Cole M, et al: Use of medications with anticholinergic effect predicts clinical severity of delirium symptoms in older medical inpatients. Arch Intern Med 161:1099-1105, 2001
66. Agostini J, Leo-Summers LS, Inouye SK: Cognitive and other adverse effects of diphenhydramine use in hospitalized older patients. Arch Intern Med 161:2091-2097, 2001
67. Massie MJ, Holland JC: The cancer patient with pain: psychiatric complications and their management. J Pain Symptom Manage 7:99-109, 1992
68. Hawley P, Forbes K, Hanks GW: Opioids, confusion and opioid rotation. Palliat Med 12:63-64, 1998
69. Daeninck PJ, Bruera E: Opioid use in cancer pain. Is a more liberal approach enhancing toxicity? Acta Anaesthesiol Scand 43:924-938, 1999
70. Morita T, Tei Y, Tsunoda J, et al: Increased plasma morphine metabolites in terminally ill cancer patients with delirium: an intra-individual comparison. J Pain Symptom Manage 23:107-113, 2002
71. Mercadante S: Opioid rotation for cancer pain: rationale and clinical aspects. Cancer 86:1856-1866, 1999
72. Mancini I, Lossignol DA, Body JJ: Opioid switch to oral methadone in cancer pain. Curr Opin Oncol 12:308-313, 2000
73. Lawlor PG, Bruera ED: Delirium in patients with advanced cancer. Hematol Oncol Clin North Am 16:701-714, 2002
74. Marcantonio ER, Juarez G, Goldman L, et al: The relationship of postoperative delirium with psychoactive medications. JAMA 272:1518-1522, 1994
75. Bruera E, Franco J, Maltoni M, et al: Changing pattern of agitated impaired mental status in patients with advanced cancer: association with cognitive monitoring hydration, and opioid rotation. J Pain Symptom Manage 10:287-291, 1995
76. Bruera E, Fainsinger R, Miller M, et al: The assessment of pain intensity in patients with cognitive failure: a preliminary report. J Pain Symptom Manage 7:267-270, 1992
77. Blalock JE: The syntax of immune-neuroendocrine communication. Immunol Today 15:504-511, 1994
78. Licinio J, King MA, Hauser P: Cytokines and brain function: relevance to interferon-α-induced mood and cognitive changes. Semin Oncol 25:30-38, 1998 (suppl 1)
79. Reichenberg A, Yirmiya R, Schuld A, et al: Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 58:445-452, 2001
80. Dunlop RJ, Campbell CW: Cytokines and advanced cancer. J Pain Symptom Manage 20:214-232, 2000
81. Bortolussi R, Fabiani F, Savron F, et al: Acute morphine intoxication during high-dose recombinant interleukin-2 treatment for metastatic renal cell cancer. Eur J Cancer 30A: 1905-1907, 1994
82. Lerner D, Stoudemire A, Rosenstein DL: Neuropsychiatric toxicity associated with cytokine therapies. Psychosomatics 40:428-435, 1999
83. Walker LG, Walker MB, Heys SD, et al: The psychological and psychiatric effects of rIL-2 therapy: a controlled clinical trial. Psychooncology 6:290-301, 1997
84. Strite D, Valentine AD, Meyers CA: Manic episodes in two patients treated with interferon alpha. J Neuropsychiatry Clin Neurosci 9:273-276, 1997
85. Meyers CA: Mood and cognitive disorders in cancer patients receiving cytokine therapy. In: Dantzer R, Wollman EE, Yirmiya R, eds. Cytokines, Stress, and Depression. New York: Plenum Publishers, 1999, 75-81
86. Hori T, Katafuchi T, Take S, et al: Neuroimmunomodulatory actions of hypothalamic interferon-alpha. Neuroimmunomodulation 5:172-177, 1998
87. Valentine AD, Meyers CA, Kling MA, et al: Mood and cognitive side effects of interferon-α therapy. Semin Oncol 25:39-47, 1998 (suppl 1)
88. Misawa A, Takeuchi Y, Hibi S, et al: FK506-induced intractable leukoencephalopathy following allogeneic bone marrow transplantation. Bone Marrow Transplant 25:331-334, 2000
89. Filley CM, Kleinschmidt-DeMasters BK: Toxic leukoencephalopathy. N Engl J Med 345:425-431, 2001
90. Zerr DM, Gooley TA, Yeung L, et al: Human herpes virus 6 reactivation and encephalitis in allogeneic bone marrow transplant recipients. Clin Infect Dis 33:764-771, 2001
91. Prieto JM, Blanch J, Atala J, et al: Psychiatric morbidity and impact on hospital length of stay among hematologic cancer patients receiving stem-cell transplantation. J Clin Oncol 20:1907-1917, 2002
92. Haire WD, Ruby EI, Gordon BG, et al: Multiple organ failure dysfunction syndrome in bone marrow transplantation. JAMA 274:1298-1295, 1995
93. Sullivan AK, Szkrumelak N, Hoffman LH: Psychological risk factors and early complications after bone marrow transplantation in adults. Bone Marrow Transplant 24:1109-1120, 1999
94. Jacobson SA: Delirium in the elderly. Psychiatr Clin North Am 20:91-110, 1997
95. Formiga F, Mascaro J, Chivite D, et al: Reversible dementia due to two coexisting diseases. Lancet 355:1154, 2000
96. Blè A, Zuliani G, Quarenghi C, et al: Cystocerebral syndrome: a case report and literature review. Aging (Milano) 13:339-342, 2001
97. Innouye SK: Delirium in hospitalized older patients: recognition and risk factors. J Geriatr Psychiatry Neurol 11:118-125, 1998
98. Inouye SK, Bogardus ST, Charpentier PA, et al: A multicomponent intervention to prevent delirium in hospitalized older patients. N Engl J Med 340:669-676, 1999
99. Roth A, Breitbart W: Psychiatric emergencies in terminally ill cancer patients. Hematol Oncol Clin North Am 10:235-259, 1996
100. Breitbart W, Strout D: Delirium in the terminally ill. Clin Geriatr Med 16:357-372, 2000
101. Morita T, Tsunoda J, Inoue S, et al: Survival prediction of terminally ill cancer patients by clinical symptoms: development of a simple indicator. Jpn J Clin Oncol 29:156-159, 1999
102. Morita T, Tsunoda J, Inoue S, et al: The palliative prognostic index: a scoring system for survival prediction of terminally ill cancer patients. Support Care Cancer 7:128-133, 1999
103. Cobb JL, Glantz MJ, Nicholas PK, et al: Delirium in patients with cancer at the end of life. Cancer Pract 8:172-177, 2000
104. Jenkins CA, Bruera E: Difficulties in diagnosing neuropsychiatric complications of corticosteroids in advanced cancer patients: two case reports. J Pain Symptom Manage 19:309-317, 2000
105. American Psychiatric Association: Practice guidelines for the treatment of patients with delirium. Am J Psychiatry 156, 1999 (suppl).
106. Breitbart W, Cohen KR: Delirium. In: Holland JC, ed: Psycho-Oncology. New York: Oxford University Press, Inc, 1998, 564-576
107. Breitbart W, Cohen K: Delirium in the terminally ill. In: Chochinov HM, Breitbart W, eds: Handbook of Psychiatry in Palliative Care. New York: Oxford University Press, Inc, 2000, 75-90
108. Cole M: Delirium: Effectiveness of systematic interventions. Dement Geriatr Cogn Disord 10:406-411, 1999
109. Rockwood K: Educational interventions in delirium. Dement Geriatr Cogn Disord 10:426-429, 1999
110. Breitbart W, Marotta R, Platt MM, et al: A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry 153:231-237, 1996
111. Akechi T, Uchitomo Y, Okamura H, et al: Usage of haloperidol for delirium in cancer patients. Support Care Cancer 4:390-392, 1996
112. Passik SD, Cooper M: Complicated delirium in a cancer patient successfully treated with olanzapine. J Pain Symptom Manage 17:219-223, 1999
113. Schwartz TL, Masand PS: The role of atypical antipsychotics in the treatment of delirium. Psychosomatics 43:171-174, 2002
114. Breitbart W, Tremblay A, Gibson C: An open trial of olanzapine for the treatment of delirium in hospitalized cancer patients. Psychosomatics 43:175-182, 2002
115. Morita T, Otani H, Tsunoda J, et al: Successful palliation of hypoactive delirium due to multi-organ failure by oral methylphenidate. Support Care Cancer 8:134-137, 2000
116. Rozans M, Dreisbach A, Lertora JJL, et al: Palliative uses of methylphenidate in patients with cancer: a review. J Clin Oncol 20:335-339, 2001